WHO.. World health statistics 2016: monitoring health for the SDGs, sustainable development goals. Geneva, Switzerland: World Health Organization; 2016.
2.
CordeiroM.F.Eyeing the brain. Acta. Neuropathologica., 132:765–766, 2016.
3.
EinarsdottirA.B., HardarsonS.H., KristjansdottirJ.V., BragasonD.T., SnaedalJ., and StefanssonE.Retinal oximetry imaging in Alzheimer's disease. J. Alzheimers. Dis., 49:79–83, 2015.
4.
FekeG.T., HymanB.T., SternR.A., and PasqualeL.R.Retinal blood flow in mild cognitive impairment and Alzheimer's disease. Alzheimers. Dement. (Amst)., 1:144–151, 2015.
MooreD., HarrisA., WudunnD., KheradiyaN., and SieskyB.Dysfunctional regulation of ocular blood flow: a risk factor for glaucoma?. Clin. Ophthalmol., 2:849–861, 2008.
7.
SilverbergG.D., MayoM., SaulT., RubensteinE., and McGuireD.Alzheimer's disease, normal-pressure hydrocephalus, and senescent changes in CSF circulatory physiology: a hypothesis. Lancet Neurol. 2:506–511, 2003.
8.
GabeltB.A.T., and KaufmanP.L.Changes in aqueous humor dynamics with age and glaucoma. Prog. Retin. Eye. Res., 24:612–637, 2005.
9.
SivakJ.M.The aging eye: common degenerative mechanisms between the Alzheimer's brain and retinal disease. Invest. Ophthalmol. Vis. Sci., 54:871–880, 2013.
10.
Ohno-MatsuiK.Parallel findings in age-related macular degeneration and Alzheimer's disease. Prog. Retin. Eye. Res., 30:217–238, 2011.
11.
JohnsonL.V., LeitnerW.P., RivestA.J., StaplesM.K., RadekeM.J., and AndersonD.H.The Alzheimer's A beta -peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration. Proc. Natl. Acad. Sci. U. S. A., 99:11830–11835, 2002.
12.
ReddyP.H.Abnormal tau, mitochondrial dysfunction, impaired axonal transport of mitochondria, and synaptic deprivation in Alzheimer's disease. Brain. Res., 1415:136–148, 2011.
13.
AlmasiehM., WilsonA.M., MorquetteB., Cueva VargasJ.L., and Di PoloA.The molecular basis of retinal ganglion cell death in glaucoma. Prog. Retin. Eye. Res., 31:152–181, 2012.
14.
SotoI., and HowellG.R.The complex role of neuroinflammation in glaucoma. Cold. Spring. Harb. Perspect. Med., 4:1–14, 2014.
BuschiniE., PirasA., NuzziR., and VercelliA.Age related macular degeneration and drusen: neuroinflammation in the retina. Prog. Neurobiol., 95:14–25, 2011.
17.
ThakkinstianA., BoweS., McEvoyM., SmithW., and AttiaJ.Association between apolipoprotein E polymorphisms and age-related macular degeneration: A HuGE review and meta-analysis. Am. J. Epidemiol., 164:813–822, 2006.
18.
LiuC.-C., KanekiyoT., XuH., and BuG.Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat. Rev. Neurol., 9:106–118, 2013.
19.
WallaceD.C., SinghG., LottM.T., HodgeJ.A., SchurrT.G., LezzaA.M., ElsasL.J., 2nd, and NikoskelainenE.K.Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy. Science. 242:1427–1430, 1988.
20.
CarelliV., LaMorgia, C., ValentinoM.L., BarboniP., Ross-CisnerosF.N., and SadunA.A.Retinal ganglion cell neurodegeneration in mitochondrial inherited disorders. Biochim. Biophys. Acta., 1787:518–528, 2009.
21.
MarescaA., la MorgiaC., CaporaliL., ValentinoM.L., and CarelliV.The optic nerve: a “mito-window”. on mitochondrial neurodegeneration. Mol. Cell. Neurosci., 55:62–76, 2013.
22.
Yu-Wai-ManP., GriffithsP.G., GormanG.S., LourencoC.M., WrightA.F., Auer-GrumbachM., ToscanoA., MusumeciO., ValentinoM.L., CaporaliL., LampertiC., TallaksenC.M., DuffeyP., MillerJ., WhittakerR.G., BakerM.R., JacksonM.J., ClarkeM.P., DhillonB., CzerminB., StewartJ.D., HudsonG., ReynierP., BonneauD., MarquesW.Jr., LenaersG., McFarlandR., TaylorR.W., TurnbullD.M., VotrubaM., ZevianiM., CarelliV., BindoffL.A., HorvathR., Amati-BonneauP., and ChinneryP.F.Multi-system neurological disease is common in patients with OPA1 mutations. Brain. 133:771–786, 2010.
23.
CarelliV., Ross-CisnerosF.N., and SadunA.A.Mitochondrial dysfunction as a cause of optic neuropathies. Prog. Retin. Eye. Res., 23:53–89, 2004.
24.
SmigrodzkiR., ParksJ., and ParkerW.D.High frequency of mitochondrial complex I mutations in Parkinson's disease and aging. Neurobiol. Aging., 25:1273–1281, 2004.
25.
GreenamyreJ.T., ShererT.B., BetarbetR., and PanovA.V.Complex I and Parkinson's disease. IUBMB. Life., 52:135–141, 2001.
26.
FletcherE.L., JoblingA.I., GreferathU., MillsS.A., WaughM., HoT., de IonghR.U., PhippsJ.A., and VesseyK.A.Studying age-related macular degeneration using animal models. Optom. Vis. Sci., 91:878–886, 2014.
27.
LinC.S., SharpleyM.S., FanW., WaymireK.G., SadunA.A., CarelliV., Ross-CisnerosF.N., BaciuP., SungE., McManusM.J., PanB.X., GilD.W., MacgregorG.R., and WallaceD.C.Mouse mtDNA mutant model of Leber hereditary optic neuropathy. Proc. Natl. Acad. Sci. U. S. A., 109:20065–20070, 2012.
28.
ZhangK., HopkinsJ.J., HeierJ.S., BirchD.G., HalperinL.S., AlbiniT.A., BrownD.M., JaffeG.J., TaoW., and WilliamsG.A.Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration. Proc. Natl. Acad. Sci. U. S. A., 108:6241–6245, 2011.
29.
GuoL., SaltT.E., LuongV., WoodN., CheungW., MaassA., FerrariG., Russo-MarieF., SillitoA.M., CheethamM.E., MossS.E., FitzkeF.W., and CordeiroM.F.Targeting amyloid-beta in glaucoma treatment. Proc. Natl. Acad. Sci. U. S. A., 104:13444–13449, 2007.
30.
DingJ.D., JohnsonL.V., HerrmannR., FarsiuS., SmithS.G., GroelleM., MaceB.E., SullivanP., JamisonJ.A., KellyU., HarrabiO., BolliniS.S., DilleyJ., KobayashiD., KuangB., LiW., PonsJ., LinJ.C., and Bowes RickmanC.Anti-amyloid therapy protects against retinal pigmented epithelium damage and vision loss in a model of age-related macular degeneration. Proc. Natl. Acad. Sci. U. S. A., 108:E279–E287, 2011.
31.
FlightM.H.Neurodegenerative disease: avoiding bad complement in Alzheimer's disease. Nat. Rev. Neurosci., 10:623–623, 2009.
32.
RicklinD., and LambrisJ.D.Complement-targeted therapeutics. Nat. Biotech., 25:1265–1275, 2007.
33.
TaskintunaI., ElsayedM.E., and SchatzP.Update on clinical trials in dry age-related macular degeneration. Middle. East. Afr. J. Ophthalmol., 23:13–26, 2016.
34.
EmerichD.F., OriveG., ThanosC., TornoeJ., and WahlbergL.U.Encapsulated cell therapy for neurodegenerative diseases: from promise to product. Adv. Drug. Deliv. Rev., 67–68:131–141, 2014.
35.
Josephy-HernandezS., JmaeffS., PirvulescuI., AboulkassimT., and SaragoviH.U.Neurotrophin receptor agonists and antagonists as therapeutic agents: an evolving paradigm. Neurobiol. Dis. 2017; 97, (Part B):139–155.
36.
KolomeyerA.M., and ZarbinM.A.Trophic factors in the pathogenesis and therapy for retinal degenerative diseases. Surv. Ophthalmol., 59:134–165, 2014.
37.
OsborneN.N.Recent clinical findings with memantine should not mean that the idea of neuroprotection in glaucoma is abandoned. Acta. Ophthalmologica., 87:450–454, 2009.
38.
TweedieD., SambamurtiK., and GreigN.H.TNF-alpha inhibition as a treatment strategy for neurodegenerative disorders: new drug candidates and targets. Curr. Alzheimer. Res., 4:378–385, 2007.
39.
McCoyM.K., and TanseyM.G.TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J. Neuroinflammation., 5:45, 2008.
40.
Cueva VargasJ.L., and Di PoloA.Neuroinflammation in glaucoma: soluble tumor necrosis factor alpha and the connection with excitotoxic damage. Neural. Regen. Res., 11:424–426, 2016.
41.
KhaliliH., LeeR.W., KhawP.T., BrocchiniS., DickA.D., and CoplandD.A.An anti-TNF-α antibody mimetic to treat ocular inflammation. Sci. Rep., 6:36905, 2016.
42.
KauperK., McGovernC., ShermanS., HeathertonP., RapozaR., StabilaP., DeanB., LeeA., BorgesS., BouchardB., and TaoW.Two-year intraocular delivery of ciliary neurotrophic factor by encapsulated cell technology implants in patients with chronic retinal degenerative diseases. Invest. Ophthalmol. Vis. Sci., 53:7484–7491, 2012.
43.
TolentinoM.Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv. Ophthalmol., 56:95–113, 2011.
44.
SaraoV., VerittiD., BosciaF., and LanzettaP.Intravitreal steroids for the treatment of retinal diseases. ScientificWorldJournal. 2014:14, 2014.
LopesV.S., and WilliamsD.S.Gene therapy for the retinal degeneration of Usher syndrome caused by mutations in MYO7A. Cold. Spring. Harb. Perspect. Med. 5, 2015.
47.
BainbridgeJWB, MehatM.S., SundaramV., RobbieS.J., BarkerS.E., RipamontiC., GeorgiadisA., MowatF.M., BeattieS.G., GardnerP.J., FeathersK.L., LuongV.A., YzerS., BalagganK., ViswanathanA., de RavelTJL, CasteelsI., HolderG.E., TylerN., FitzkeF.W., WeleberR.G., NardiniM., MooreA.T., ThompsonD.A., Petersen-JonesS.M., MichaelidesM., van den BornL.I., StockmanA., SmithA.J., RubinG., and AliR.R.Long-term effect of gene therapy on Leber's congenital amaurosis. N. Engl. J. Med., 372:1887–1897, 2015.
48.
MeadB., BerryM., LoganA., ScottR.A.H., LeadbeaterW., and SchevenB.A.Stem cell treatment of degenerative eye disease. Stem. Cell. Res., 14:243–257, 2015.
49.
Yu-Wai-ManP., VotrubaM., BurtéF., LaMorgia, C., BarboniP., and CarelliV.A neurodegenerative perspective on mitochondrial optic neuropathies. Acta. Neuropathol., 132:789–806, 2016.
50.
HartN.J., KoronyoY., BlackK.L., and Koronyo-HamaouiM.Ocular indicators of Alzheimer's: exploring disease in the retina. Acta. Neuropathol., 132:767–787, 2016.
51.
NormandoE.M., DavisB.M., De GroefL., NizariS., TurnerL.A., RavindranN., PahlitzschM., BrentonJ., MalaguarneraG., GuoL., SomavarapuS., and CordeiroM.F.The retina as an early biomarker of neurodegeneration in a rotenone-induced model of Parkinson's disease: evidence for a neuroprotective effect of rosiglitazone in the eye and brain. Acta. Neuropathol. Commun., 4:1–15, 2016.
